U.S. patent application number 16/756610 was filed with the patent office on 2020-12-17 for marburg virus vaccine with human replication-deficient adenovirus as vector.
This patent application is currently assigned to Academy of Military Medical Science, PLA. The applicant listed for this patent is Academy of Military Medical Science, PLA. Invention is credited to Wei Chen, Ling Fu, Lihua Hou, Xiaohong Song, Busen Wang, Yanbo Wen, Shipo Wu, Jinlong Zhang, Zhe Zhang.
Application Number | 20200392188 16/756610 |
Document ID | / |
Family ID | 1000005092945 |
Filed Date | 2020-12-17 |
![](/patent/app/20200392188/US20200392188A1-20201217-D00001.png)
![](/patent/app/20200392188/US20200392188A1-20201217-D00002.png)
![](/patent/app/20200392188/US20200392188A1-20201217-D00003.png)
![](/patent/app/20200392188/US20200392188A1-20201217-D00004.png)
![](/patent/app/20200392188/US20200392188A1-20201217-D00005.png)
![](/patent/app/20200392188/US20200392188A1-20201217-D00006.png)
![](/patent/app/20200392188/US20200392188A1-20201217-D00007.png)
![](/patent/app/20200392188/US20200392188A1-20201217-D00008.png)
![](/patent/app/20200392188/US20200392188A1-20201217-D00009.png)
![](/patent/app/20200392188/US20200392188A1-20201217-D00010.png)
![](/patent/app/20200392188/US20200392188A1-20201217-D00011.png)
View All Diagrams
United States Patent
Application |
20200392188 |
Kind Code |
A1 |
Chen; Wei ; et al. |
December 17, 2020 |
MARBURG VIRUS VACCINE WITH HUMAN REPLICATION-DEFICIENT ADENOVIRUS
AS VECTOR
Abstract
The present invention relates to a nucleotide sequence as shown
in SEQ ID NO: 1 for encoding a Marburg virus envelope glycoprotein,
and to a human replication-deficient recombinant adenovirus capable
of expressing the nucleotide sequence and a preparation method
therefor, as well as an application thereof in the preparation of a
vaccine against Marburg virus disease. The vaccine uses an E1 and
E3 deleted replication-deficient human type-5 adenovirus as a
vector, and HEK293 cells integrating an adenovirus E1 gene as a
packaging cell line, and a protective antigen gene carried is a
codon-optimized Marburg virus Angola strain envelope glycoprotein
gene. After codon optimization of the envelope glycoprotein gene,
significant expression of envelope glycoprotein can be detected in
transfected cells.
Inventors: |
Chen; Wei; (Beijing, CN)
; Wu; Shipo; (Beijing, CN) ; Hou; Lihua;
(Beijing, CN) ; Wen; Yanbo; (Beijing, CN) ;
Zhang; Zhe; (Beijing, CN) ; Wang; Busen;
(Beijing, CN) ; Song; Xiaohong; (Beijing, CN)
; Zhang; Jinlong; (Beijing, CN) ; Fu; Ling;
(Beijing, CN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Academy of Military Medical Science, PLA |
Beijing |
|
CN |
|
|
Assignee: |
Academy of Military Medical
Science, PLA
Beijing
CN
|
Family ID: |
1000005092945 |
Appl. No.: |
16/756610 |
Filed: |
August 27, 2018 |
PCT Filed: |
August 27, 2018 |
PCT NO: |
PCT/CN2018/102408 |
371 Date: |
April 16, 2020 |
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 31/14 20180101;
A61K 39/12 20130101; C12N 2760/14222 20130101; C12N 2760/14234
20130101; A61K 2039/57 20130101; C12N 2710/10021 20130101; C12N
2710/10051 20130101; A61K 2039/575 20130101; C07K 14/005 20130101;
C12N 7/00 20130101; C12N 2710/10043 20130101 |
International
Class: |
C07K 14/005 20060101
C07K014/005; C12N 7/00 20060101 C12N007/00; A61K 39/12 20060101
A61K039/12; A61P 31/14 20060101 A61P031/14 |
Foreign Application Data
Date |
Code |
Application Number |
May 7, 2018 |
CN |
201810428286.1 |
Claims
1. An isolated nucleic acid molecule encoding a Marburg virus
envelope glycoprotein, wherein the said isolated nucleic acid
molecule has a sequence shown in SEQ ID NO: 1.
2. A vector containing the nucleic acid molecule of claim 1.
3. The vector of claim 2, wherein the vector is pDC316.
4. A human replication-deficient recombinant adenovirus capable of
expressing nucleic acid molecule of claim 1.
5. The recombinant adenovirus of claim 4, wherein the recombinant
adenovirus derived from AdMax adenovirus system.
6. A use of recombinant adenovirus of claim 5 in the preparation of
vaccine for Marburg virus disease prevention.
7. The use of claim 6, wherein the recombinant adenovirus is
prepared as an injection.
8. A method of preparation of the human replication-deficient
recombinant adenovirus of claim 5, including the following steps:
(1) Construction of a shuttle plasmid vector containing an isolated
nucleic acid molecule encoding a Marburg virus envelope
glycoprotein; (2) Transfection of the vector of step (1) into host
cells together with backbone plasmids; (3) Cultivation of the host
cells of step (2); (4) Harvest of human replication-deficient
recombinant adenoviruses released from the cells of step (3).
9. The method of claim 8, wherein the vector of step (1) is
pDC316.
10. The method of claim 8, wherein the backbone plasmid of step (2)
is pBHGlox.DELTA.E1, 3Cre.
11. The method of claim 8, wherein the cell of step (3) is HEK293
cell.
12. The Method of claim 8, wherein the recombinant adenoviruses of
step (4) is extracted and purificated through a two-step column
chromatography with source 30Q and sepharose 4ff.
Description
TECHNICAL FIELD
[0001] The present invention relates to an isolated nucleic acid
molecule, to be specific, to an isolated nucleic acid molecule
encoding a virus envelope glycoprotein, belonging to the field of
genetic engineering technology.
BACKGROUND TECHNOLOGY
[0002] Marburg virus (MARV) is a kind of hemorrhagic fever virus,
which is a member of Filoviridae family. MARV can cause Marburg
virus disease, a viral hemorrhagic fever in humans and non-human
primates, with a mortality rate of up to 90%. MARV is an
exceptionally dangerous pathogen, which is classified as biosafety
level-4 pathogen by WHO (requires to conduct related operations in
biosafety level 4 laboratory), as category A priority pathogen by
National Institutes of Health and National Institute of Allergy and
Infectious Diseases, and as category A bioterrorism agent by
Centers for Disease Control and Prevention, USA.
[0003] Marburg virus is named after Marburg, Germany, which was
initially detected in 1967 after small-scale outbreaks in Marburg
and Frankfurt in Germany, and in Belgrade in Yugoslavia, when
laboratory workers were exposed to tissues of MARV-infected African
green monkeys imported from Uganda, resulting in 31 cases of
infection and 7 deaths.
[0004] Marburg virus is mainly endemic in sub-Saharan Africa, with
fruit bats as the potential hosts. In human, MARV spreads through
contaminated body fluids exposure via sexual intercourse and
contact with damaged skin, and the funeral rituals in Africa is a
major risk of virus transmission. Two large outbreaks of MARV
occurred in Congo between 1998 to 2000, leading to 154 cases of
infection and 128 deaths, with a mortality rate of 83%; and in
Angola between 2004 to 2005, leading to 252 cases of infection and
227 deaths, with a fatality rate of 90%.
[0005] Marburg virus strains consist of Ravn virus and Marburg
virus, and the latter can be further divided into strain A and
strain B. Strain A is isolated from Uganda (5 strains in 1967),
Kenya (1980) and Angola (2004-2005); and strain B is isolated from
the Republic of the Congo (1999-2000) and Uganda (2007-2009). The
gene homology of Ravn virus and Marburg virus is approximate 80%,
and that of strain A and strain B is greater than 90%.
[0006] Marburg virus glycoprotein (MARV-GP) is the unique surface
protein of Marburg virus envelope. MARV-GP plays a key role in the
pathogenesis of Marburg virus, which is also the main target
protein that induces the body to produce a protective immune
response. MARV-GP is basically used as the target antigen for
Marburg virus vaccines under development currently, including DNA
vaccines, subunit vaccines, non-replicating and replicating
virus-vectored vaccines. Several vaccines have achieved good immune
protective effect in animal models, and some have entered clinical
trials, including DNA vaccines and modified vaccinia virus Ankara
(MVA)-vectored Ebola-Marburg combined vaccine, and chimpanzee
adenovirus type 3 (ChAd3)-vectored Marburg vaccine. However, as of
April 2018, there is no approved Marburg vaccine in the world.
[0007] AdMax system consists of LoxP site-containing shuttle
plasmid, backbone plasmid, and HEK293 cell line. Recombinant
adenovirus is generated by genetic recombination of exogenous gene
sequence with the backbone plasmid in HEK293 cells after the DNA
fragment is inserted into the shuttle plasmid. The recombinant
adenovirus packaged by AdMax system is a E1 and E3 deleted
replication-deficient adenovirus. And the vaccine based on this has
the advantage of high safety. Furthermore, AdMax system also has
other advantages, such as efficient, stable, convenient and fast
packaging and high yield. Previously, the inventors of the present
application used AdMax system to successfully prepare a recombinant
Ebola virus disease vaccine with Zaire-type Ebola virus Makona
strain envelope glycoprotein as the target antigen, which is an
example of the rapid development of the vaccine, from gene
synthesis to clinical trials within five months, highlighting the
advantages of the Admax system.
[0008] The expression level of target protein is an essential
factor for the immune response of the live virus-vectored vaccine.
High-level expression of target protein can achieve good immune
response with reduced immune dose, leading to the decrease in the
live virus vector-related adverse reactions of vaccinees.
Therefore, the immune response of the vaccine can be enhanced by
higher expression and secretion to outside of the cell of envelope
glycoprotein via codon optimization of MARV-GP gene and change of
the signal peptide.
SUMMARY OF THE PRESENT INVENTION
Technical Problem
[0009] In 2014, the largest Ebola outbreak occurred in West Africa,
causing more than 28,000 cases of infection and over 11,000 deaths.
Ebola virus and Marburg virus are members of Filoviridae family,
and as the most dangerous viruses, both can cause large-scale
epidemics, which may be used as biological weapons for biological
warfare or biological terror. Therefore, the development of a safe
and effective Marburg virus vaccine is crucial. Based on the real
threat of Marburg virus and the successful experience of
preparation of a recombinant Ebola virus disease vaccine by using
AdMax system, the applicant intends to achieve high-level
expression of envelope glycoprotein in eukaryotic cells through
codon optimization of MARV-GP, and to provide a recombinant
adenovirus-vectored Marburg virus disease vaccine with the capacity
of inducing higher levels of humoral and cellular immune responses
at the same dose level.
Solutions to Technical Problem
[0010] For the above purposes, the present invention first provides
an isolated nucleic acid molecule as shown in SEQ ID NO: 1 for
codon optimization of MARV-GP gene of Marburg virus disease
vaccine. The recombinant adenovirus-vectored Marburg virus disease
vaccine is obtained after being packaged with an E1 and E3 deleted
replication-deficient human type-5 adenovirus as a vector, and
HEK293 cells integrating an adenovirus E1 gene as a packaging cell
line.
[0011] The present invention also provides a vector containing the
above isolated nucleic acid molecule.
[0012] In a preferred embodiment, the vector is pDC316.
[0013] The present invention also provides a human
replication-deficient recombinant adenovirus capable of expressing
the above isolated nucleic acid molecule.
[0014] In a preferred embodiment, the recombinant adenovirus vector
is derived from the AdMax adenovirus system.
[0015] The present invention also provides a use of the
above-mentioned recombinant adenovirus vector in preparation of the
vaccine for Marburg virus disease prevention.
[0016] In a preferred embodiment, the recombinant adenovirus is
prepared as an injection powder in the above application.
[0017] Finally, the present invention provides a method for
preparing the above-mentioned recombinant adenovirus capable of
expressing MARV-GP. The method includes the following steps:
[0018] (1) Construction of a shuttle plasmid vector containing an
isolated nucleic acid molecule encoding a MARV-GP;
[0019] (2) Transfection of the vector of step (1) into host cell
together with backbone plasmid;
[0020] (3) Cultivation of the host cells of step (2);
[0021] (4) Extraction of human replication-deficient recombinant
adenoviruses capable of expressing MARV-GP from the host cells of
step (3).
[0022] Preferably, the vector of step (1) is pDC316.
[0023] Preferably, the backbone plasmid of step (2) is
pBHGlox.sup..DELTA.E1, 3Cre. Both plasmids belong to the AdMax
adenovirus system, and are used together in host cell for packaging
of recombinant adenovirus containing the nucleotide sequence
encoding MARV-GP.
[0024] Preferably, the cells of step (3) are HEK293 cells.
[0025] Preferably, two-step column chromatography with Source 30 Q
and Sepharose 4 FF is used in step (4) for purification of Marburg
virus disease vaccine.
Beneficial Effects of the Present Invention
[0026] After animals are immunized with the recombinant adenovirus
capable of expressing MARV-GP provided by the present invention,
which is used as the Marburg virus disease vaccine, strong cellular
and humoral immune response are induced in a short time. Challenged
with the mouse adapted strain of Marburg virus 4 weeks post
immunization by the vaccine, all immunized mice survive, while all
control mice die within 6 to 8 days after challenged, indicating
efficacious protection of the vaccine against Marburg virus. The
preparation of the vaccine is simple, which can be produced
scale-up in a short period in response to emergent Marburg
outbreaks and bioterrorism attacks. Moreover, the expression of
MARV-GP can only be detected in transfected cells by the codon
optimized gene encoding the vaccine target protein, and the humoral
and cellular immune responses induced by the recombinant
adenovirus-vectored vaccine packaged on the basis of this codon
optimized gene for Marburg virus disease are significantly
improved. The improvement of immune level is of great significance
to the prevention against Marburg virus infection
BRIEF DESCRIPTION OF THE DRAWINGS
[0027] FIG. 1 provides the map of the shuttle plasmid.
[0028] FIG. 2 is a graph of the identification of in vitro
expression of MARV-GP.
[0029] FIG. 3 depicts PCR identification of primary virus
strain.
[0030] FIG. 4 is the identification of MARV-GP expression of the
primary virus strain of Marburg virus disease vaccine.
[0031] FIG. 5 shows chromatography process of Source 30Q.
[0032] FIG. 6 provides PCR identification of samples of purified
Marburg virus disease vaccine.
[0033] FIG. 7 is a graph of the identification of MARV-GP
expression of samples of purified Marburg virus disease vaccine
candidate strains.
[0034] FIG. 8 depicts changes in serum IgG antibody level over
time.
[0035] FIG. 9 is the maintenance of serum IgG antibody level.
[0036] FIG. 10 shows the statistical analysis of the results of
flow cytometry with intracellular cytokine staining.
[0037] FIG. 11 provides CD4.sup.+ T cell immune response induced by
different doses of Ad5-MAGPopt.
[0038] FIG. 12 is a graph of CD8.sup.+ T cell immune response
induced by different doses of Ad5-MAGPopt.
[0039] FIG. 13 depicts CD154.sup.+CD4.sup.+ T cell response induced
by different doses of Ad5-MAGPopt.
[0040] FIG. 14 is the statistical analysis and representative
results of ELISPOT detection of IFN-.gamma. secretion.
[0041] FIG. 15 shows IFN-.gamma. secretion induced by different
doses of Ad5-MAGPopt.
[0042] FIG. 16 provides the protective effect of Marburg virus
disease vaccine on mouse model.
[0043] FIG. 17 is a graph of the change of body weight of mice
after challenge.
EXAMPLES
[0044] The present invention is further described with specific
examples below, and the advantages and features of the present
invention will become clearer with the description. However, these
examples are only exemplary, and do not constitute any limitation
on the protection scope defined by the claims of the present
invention.
Example 1. Preparation of Human Replication-Deficient
Adenovirus-Vectored Marburg Virus Disease Vaccine
[0045] 1. Optimization and Synthesis of MARV-GP Gene
[0046] The envelope glycoprotein of the Marburg virus strain
ang0998 (Genebank ID: DQ447660.1) was selected as the target
antigen of the Marburg virus vaccine, which was endemic in Angola,
Africa, between 2004 and 2005.
[0047] Upgene software (Gao, W. Rzewski, A. Sun, H. Robbins, P. D.
& Gambotto, A. UpGene: Application of a web-based DNA codon
optimization algorithm. Biotechnol Prag, 2004. 20(2): p. 443-8.)
was used for optimizing the codon of the gene. The rare codons was
changed by the optimal codons in host cells, meanwhile, the
stability of post-transcription mRNA was strengthened, which made
it more suitably expressed in eucaryotic host cell.
[0048] After gene optimization, The variation of the MARV-GP gene
sequence from the original GP gene sequence was 26.1%. Meanwhile,
the original signal peptide (1aa-18aa) was replaced by the signal
peptide of Tissue Plasminogen Activator(tPA), then Kozak sequence
was added in front of the translation initiation codon, with
restriction enzyme sites HindIII and SalI as the upstream and
downstream restriction site, respectively. The MARV-GP gene was
synthesized for recombinant plasmid construction after gene
optimized and signal peptide replaced. Besides, the original
sequence of the MARV-GP gene was also synthesized as a control. See
SEQ ID NO:1 for the optimized MARV-GP gene sequence (with HindIII
and SalI as the restriction sites), and see SEQ ID NO:2 for the
original MARV-GP gene sequence (with HindIII and SalI as the
restriction sites).
[0049] 2. Construction of Vectors and Identification of In Vitro
Expression of MARV-GP
[0050] 2.1 Construction of Vectors
[0051] The above synthesized gene sequence is double-digested with
HindIII and SalI, and the target gene fragment is recovered and
connected to the shuttle plasmid pDC316 of the AdMax adenovirus
system (Microbix Biosystems Inc., Canada), and then is transformed
into DH5-.alpha. competent cells and coated on Amp.sup.r LB plate.
Monoclones are selected for colony PCR identification, and
sequenced. Plasmid of MARV-GP gene sequence without codon
optimization is marked as pDC316-MAGP, whereas plasmid of MARV-GP
gene with codon optimization is marked as pDC316-MAGPopt. The
plasmid map is shown in FIG. 1, wherein A indicates the plasmid map
of pDC316-MAGPopt, and B represents the plasmid map of
pDC316-MAGP.
[0052] 2.2 Identification of In Vitro Expression of MARV-GP
[0053] Each of the two shuttle plasmids constructed above and
pDC316 vector are transfected into HEK293 cells by using TurboFect
Transfection Reagent (Thermo Scientific, #R0531), and the cells are
collected at 48 hours post transfection for Western blot detection.
The experimental method is as follows:
[0054] Transfection: One day before the experiment, HEK293 cells
are inoculated into a 6-well plate with 8.times.10.sup.5 cells/well
and cultured overnight at 37.degree. C. in 5% CO.sub.2 incubator. 1
hour prior to transfection, the medium is changed to fresh MEM
medium containing 2% FBS, with 2 mL per well. During transfection,
2 .mu.g of corresponding plasmid is taken for each transfection
well, added to 200 .mu.L of FBS-free MEM medium, and mixed. 3 .mu.L
of transfection reagent is added and mixed gently. The mixture is
incubated at room temperature for 15 min. The mixture of plasmid
and transfection reagent is gently dripped into the 6-well plate
and mixed gently. Cells are cultured at 37.degree. C. in 5%
CO.sub.2 incubator. 5 hours later, the medium is changed to a fresh
MEM medium with 10% FBS. Cells are collected at 48 hours post
transfection to prepare samples for Western blot detection.
[0055] Sample preparation: 48 hours post transfection, the medium
is carefully aspirated and discarded, and cells are washed once
with PBS. The 6-well plate is placed on ice, and 120 .mu.L of cell
lysis buffer (1.times.SDS-PAGE buffer containing 50 mmol/L DTT,
1.times.protease inhibitor, and 250 U/mL nuclease) is added to each
well. Lysed cells are collected by a cell scraper, and transferred
to a 1.5 mL EP tube and placed into an ice bath for 15 min. Cells
are heated at 95.degree. C. for 5 min, then cooled in an ice bath,
and centrifuged at 12000 rpm for 5 minutes at 4.degree. C. The
supernatant is collected, dispensed and stored frozen for Western
blot detection.
[0056] Western blot detection: 10-well 12% SDS-PAGE gel is used for
SDS-PAGE, and the samples are loaded with 10 .mu.L per well.
Electrophoresis conditions: 80 V, 15 min; 180 V, until bromophenol
blue migrates out of the gel. The protein on the SDS-PAGE gel is
transferred to nitrocellulose membrane by an electric transfer
apparatus at 300 mA for 1 h. After electroporation, the
nitrocellulose membrane is blocked with 5% skim milk for 1 h, and
then anti-MARV-GP rabbit polyclonal antibody (Abcam, ab190459) is
added at dilution of 1:2000. The mixture is left at 4.degree. C.
overnight. The membrane is washed 4 times with Western blot wash
buffer and shaken on the shaker for 7 minutes each time. Then
HRP-labeled goat anti-rabbit IgG antibody (CST, 7074S) diluted
1:5000 in 5% skim milk is added, and the mixture is incubated for 1
hour at room temperature. The membrane is washed times with Western
blot wash buffer. Immobilon.TM. Western Chemiluminescent HRP
Subsrate (MILLIPORE, Cat. No. WBKLS0500) is used for
chemiluminescence reaction, and chemiluminescence imager is used to
capture images at different exposure times.
[0057] GAPDH is used as the loading control, and results are shown
in FIG. 2, wherein lane 1 indicates the cells transfection of
pDC316 vector; lane 2 depicts the cells transfection of
codon-optimized shuttle plasmid pDC316-MAGPopt; and lane 3
represents cells transfection of non-codon-optimized shuttle
plasmid pDC316-MAGP. The results suggest that expression of MARV-GP
can only be detected in transfected HEK293 cells with the
codon-optimized shuttle plasmid pDC316-MAGPopt.
[0058] 3. Packaging, Preparation and Identification of the
Vaccine
[0059] 3.1 Packaging of the Vaccine
[0060] The above constructed vectors pDC316-MAGP and pDC316-MAGPopt
are respectively co-transfected into HEK293 cells with the backbone
plasmid pBHGlox.sup..DELTA.E1, 3 Cre of the AdMax adenovirus
system, in order to package the recombinant adenovirus. The process
is as follows:
[0061] a) On the day before transfection, HEK293 cells are
inoculated into a 6-well plate with 5.times.10.sup.5 cells/well,
with MEM+10% FBS as the medium, and are cultured overnight at
37.degree. C. in 5% CO.sub.2 incubator.
[0062] b) On the day of transfection, cells continue to be cultured
in fresh MEM medium with 10% FBS. When cells grow to cover 80%-90%
of the well bottom, the backbone plasmid (pBHGlox.sup..DELTA.E1, 3
Cre) and shuttle plasmid are co-transfected to HEK293 cells with
Lipofectamine.TM. 2000 liposomes according to the instruction of
the reagent. The specific steps are as follows:
[0063] (1) 4 .mu.g of backbone plasmid and 1 .mu.g of shuttle
plasmid are taken for each transfection well, and mixed.
[0064] (2) The plasmids are diluted with 300 .mu.L of serum-free
MEM medium and left at room temperature for 5 min.
[0065] (3) 10 .mu.L of liposomes are taken and diluted with 300
.mu.L of serum-free MEM medium, left at room temperature for 5
min.
[0066] (4) The plasmids of step (2) and liposomes in step (3) are
mixed, and left at room temperature for 30 minutes in the dark.
Then the mixture is added to the cells.
[0067] c) On the next day after transfection, the cells which cover
the whole bottom of the well are passaged into a 25 cm.sup.2 cell
culture flask, and continue to be cultured in MEM medium containing
5% FBS. Daily observation is conducted, and cells are passaged into
a 75 cm.sup.2 cell culture flask when they cover the bottom of the
flask. Daily observation for the cells is performed. The
recombinant virus generates when the cells become large and round,
in shape of grape, and obvious plaques begin to appear. Virus are
collected when cell lesion appears and the cells are detached from
the bottom.
[0068] The cell culture flasks with new virus are frozen in a
refrigerator at -70.degree. C. and thawed in a water bath at
37.degree. C. for three times, to let virus fully release from the
cells. The frozen-thawed solution is centrifuged at 3000 rpm for 5
min, and the supernatant containing virus is collected. The
supernatant is the primary virus strain (P1), and used for
subsequent amplification of a large number of viruses.
[0069] The primary virus strains of the recombinant adenovirus with
different MARV-GP gene are recorded as Ad5-MAGP and Ad5-MAGPopt,
respectively.
[0070] 3.2 Identification of the Primary Virus Strain
[0071] 3.2.1 PCR Amplification of MARV-GP Gene and Sequencing
[0072] The following universal primers of pDC316 vector are used to
amplify the sequence of MARV-GP:
TABLE-US-00001 pDC316-F: ACGTGGGTATAAGAGGCG, and pDC316-R:
CGATGCTAGACGATCCAG.
[0073] Primary virus strain genomes of Ad5-MAGP and Ad5-MAGPopt are
extracted according to the instruction of viral genomic DNA/RNA
extraction kit (DP315, Tiangen Biotech), and identified by PCR with
the above primers.
[0074] PCR amplification conditions are:
TABLE-US-00002 TABLE 1 Genomic DNA of samples for test 1 .mu.L
Upstream primer 0.4 .mu.L Downstream primer 0.4 .mu.L dNTP 1.6
.mu.L LA Taq DNA Polymerase 0.2 .mu.L 10 .times. LA Buffer 2 .mu.L
ddH2O 14.4 .mu.L
[0075] Reaction procedure:
TABLE-US-00003 94.degree. C., 5 min. 94.degree. C. 30 s 56.degree.
C. 30 s {close oversize brace} 30 cycles 72.degree. C. 120 s
72.degree. C., 10 min.
[0076] The results of PCR amplification are shown in FIG. 3, where
lane 1 indicates DNA ladder (Takara, DL2000); lane 2 shows DNA/RNA
amplification products of Ad5-MAGP primary virus strain; lane 3
depicts DNA/RNA amplification products of Ad5-MAGPopt primary virus
strain; and 4 represents the amplification products of plasmid
pDC316-MAGPopt (positive control). Results suggest correct band
size after amplification. Target bands 2 and 3 are gel-recovered
and sequenced. The alignment results indicate that the sequences
tested are completely correct.
[0077] 3.2.2 Identification of MARV-GP Expression of Marburg Virus
Disease Vaccine Candidate Strain.
[0078] HEK293 cells are infected with Ad5-MAGP and Ad5-MAGPopt, and
collected 48 hours later for Western blot detection of MARV-GP. No
MARV-GP is detected for Ad5-MAGP infection. However MARV-GP is
detected for Ad5-MAGPopt infection, as shown in FIG. 4, wherein
lane 1 indicates blank cells; lane 2 depicts Ad5-MAGP infected
cells; and lane 3 represents Ad5-MAGPopt infected cells.
[0079] 3.3 Expanded Culture and Purification of Ad5-MAGPopt and
Ad5-MAGP
[0080] 3.3.1 Small-Scale Culture of Ad5-MAGPopt and Ad5-MAGP
[0081] HEK293 cells are suspension-cultured at 37.degree. C. in 5%
CO.sub.2, at 130 rpm. When infected with the virus strain, cells
with a viability greater than 95% are diluted to 1.0.times.10.sup.6
cells/mL, with 1 L as the final volume. HEK293 cells are infected
with recombinant adenovirus at MOI 10, and are cultured at
37.degree. C. in 5% CO.sub.2, with shaken at 130 rpm. Samples are
collected every 24 hours for the measurement of cell viability and
density. About 72 hours post inoculation, when the cell viability
drops to below 40%, 10 mL tween-20 (final concentration, 1%) is
added into the flasks and the flasks continue to be shaken for 1
hour at 130 rpm. The cell culture harvest is centrifuged at 6000
rpm for 30 min, and the supernatant is taken and stored frozen at
-70.degree. C. The precipitate is resuspended in an equal volume of
20 mM Tris, 250 mM NaCl, 1 mM MgCl.sub.2, 1% tween-20, pH 7.5, and
the mixture is shaken at 37.degree. C., 130 rpm for 1 h. The
suspension is centrifuged at 6000 rpm for 45 min, then stored
frozen at -70.degree. C.
[0082] 3.3.2 Purification of Ad5-MAGPopt and Ad5-MAGP
[0083] The above recombinant adenovirus culture harvest stored
frozen at -70.degree. C. are thawed for purification. The harvest
is ultrafiltrated and concentrated to 500 mL with 300 kDa membrane,
and added with an equal volume of 20 mM Tris+150 mM NaCl+2 mM
MgCl.sub.2 pH7.5 (solution A). Finally 300 mL viral solution is got
after 3 times of ultrafiltration. Benzonase (30 U/mL) is added, and
the mixture is left in a water bath at 37.degree. C. for 4 h.
[0084] Two-step column chromatography with Source 30Q and Sepharose
4 FF are used to purify adenovirus particles. The column
chromatography in the first step is to remove most of the
miscellaneous protein and to collect the eluted peaks, whereas the
column chromatography in the second step is to remove the
miscellaneous DNA residue and some miscellaneous protein, and the
samples collected are flow-through samples. The specific process is
as follows:
[0085] Chromatography with Source 30Q: The column is equilibrated
with solution A, and samples are loaded at a flow rate of 5 mL/min.
After sample loading, solution A is used to equilibrate the column
at 10 mL/min for 50 min. 0%-30% solution B is used for gradient
elution, and the elution peaks are harvested in separate tubes.
Finally, 100% solution B is used for elution. Solution B is 20 mM
Tris+2 M NaCl+2 mM MgCl.sub.2 pH7.5. Elution peaks are shown in
FIG. 5.
[0086] Chromatography with Sepharose 4 FF: The above elution peaks
are further purified with Sepharose 4 FF. The mobile phase is
solution A, the flow rate is 5 mL/min, the pressure limit is 0.3
MPa, and the flow-through are harvested. Purified adenoviral
particles are filtration-sterilized through a 0.22-.mu.m filter and
stored in a refrigerator at -70.degree. C.
[0087] 3.4 Identification and Titer Determination of Ad5-MAGPopt
and Ad5-MAGP
[0088] 3.4.1 PCR Amplification of MARV-GP Sequence and
Sequencing
[0089] The method and process are the same as those described in
section 3.2.1, and results are shown in FIG. 6, wherein lane 1
indicates DNA ladder (Takara, DL2000); lane 2 shows DNA/RNA
amplification products of purified Ad5-MAGP; lane 3 depicts DNA/RNA
amplification products of purified Ad5-MAGPopt; and lane 4
represents negative control. Results suggest that target sequence
are detected in the purified Ad5-MAGPopt and Ad5-MAGP. Sequencing
results show the DNA sequences from Ad5-MAGPopt and Ad5-MAGP are
totally correct.
[0090] 3.4.2 Western Blot Detection
[0091] HEK293 cells are infected with Ad5-MAGPopt and Ad5-MAGP at
MOI 10, and cells are collected 48 hours post infection for Western
blot detection of MARV-GP. Results are shown in FIG. 7, wherein
lane 1 indicates Ad5-MAGPopt infected cells; and lane 2 indicates
Ad5-MAGP infected cells. MARV-GP can be detected only in
Ad5-MAGPopt-infected cells, not in Ad5-MAGP-infected cells.
[0092] 3.4.3 Titer Determination
[0093] Clontech Adeno-X.TM. Rapid Titer Kit is used to measure the
titer of the purified Ad5-MAGPopt and Ad5-MAGP. The procedure is
conducted according to the instructions of the kit, and the
specific method is as follows:
[0094] a) HEK293 cells are seeded into a 24-well plate with
5.times.10.sup.5 cells/mL, 0.5 mL per well, with MEM+10% FBS as the
medium.
[0095] b) The adenovirus to be detected are diluted 10-fold with
medium, from 10.sup.-2 to 10.sup.-6, to prepare a series of diluted
virus samples, and 50 .mu.L per well is added to the cells.
[0096] c) Cells are cultured at 37.degree. C. in 5% CO.sub.2
incubator for 48 hours.
[0097] d) Cell medium is aspirated and discarded to allow cells to
dry slightly (do not over-dry). 0.5 mL of ice-cold methanol is
gently added to each well, and the plate is left at -20.degree. C.
for 10 minutes to fix the cells.
[0098] e) Methanol is aspirated and discarded, and cells are gently
washed 3 times with PBS+1% BSA. 0.25 mL of Anti-Hexon antibody
diluent (1:1000 dilution) is added to each well, and incubate at
37.degree. C. for 1 hour.
[0099] f) Anti-Hexon antibody is aspirated and discarded, and cells
are gently washed 3 times with PBS+1% BSA. 0.25 mL of HRP-labeled
rat anti-mouse antibody (1:500 dilution) is added to each well, and
incubate at 37.degree. C. for 1 h.
[0100] g) Prior to removing the Rat Anti-Mouse Antibody (HRP
conjugate), prepare DAB working solution by diluting 10.times.DAB
Substrate 1:10 with 1.times. Stable Peroxidase Buffer. Allow the
1.times.DAB working solution to come to room temperature.
[0101] h) The rat anti-mouse antibody is aspirated and discarded,
and cells are gently washed 3 times with PBS+1% BSA. 0.25 mL of DAB
working solution is added to each well, and incubate at room
temperature for 10 min.
[0102] i) DAB working solution is aspirated and discarded, and
cells are gently washed 2 times with PBS.
[0103] j) Brown/black positive cells are counted under a
microscope. At least 3 fields are randomly counted for each well,
and the mean number of positive cells is calculated.
[0104] h) Infection titer (ifu/mL) is calculated, with the
following formula:
Infection titer ( ifu / mL ) = ( infected cells / field ) .times. (
fields / well ) volume virus ( mL ) .times. ( dilution factor )
##EQU00001##
[0105] Results of titer determination show that the infection titer
of the elution peak of Sepharose 4 FF chromatography can reach
1.0.times.10.sup.10 ifu/mL or above.
Example 2. Immunological Evaluation of Ad5-MAGPopt and Ad5-MAGP in
a Mouse Model
[0106] 1. Materials
[0107] 1.1. Animals
[0108] SPF female BALB/c mice (age 4-6 weeks) are used, which are
purchased from Beijing Weitong Lihua Experimental Animal Technology
Co., Ltd and raised in the animal center of of Academy of Military
Medical Science.
[0109] 1.2. Reagent
[0110] Fluorescently labeled antibodies FITC anti-mouse CD8a (Clone
5H10-1), PE anti-mouse IFN.gamma. (Clone XMG1.2), PerCP/Cy5.5
anti-mouse CD3 (Clone 17A2), Alexa Fluor.RTM. 700 anti-mouse CD4
(Clone RM4-5), APC/Cy7 anti-mouse CD14 (Clone Sa14-2), APC/Cy7
anti-mouse CD19 (Clone 6D5), Brilliant Violet 421.TM. anti-mouse
CD107a (Clone 1D4B), Brilliant Violet 510.TM. anti-mouse CD154
(Clone MR1), Brilliant Violet 605.TM. anti-mouse IL-2 (Clone
JES6-5H4) and erythrocyte lysis buffer are purchased from
Biolegend. Fluorescently labeled antibodies PE/Cy7 anti-mouse TNF
(Clone MP6-XT22), Mouse BD Fc Block.TM., BD Perm/Wash.TM. Buffer,
BD Cytofix/Cytoperm.TM. Fixation and Permeabillization Solution, BD
GolgiStop", BD GolgiPlug.TM., BD" ELISPOT mouse IFN.gamma. Set,
BD.TM. ELISPOT AEC substrate set and flow tubes are purchased from
BD. LIVE/DEAD.TM. Fixable Near-IR Dead Cell Stain Kit is purchased
from Invitrogen, BSA is purchased from Merck, HRP-labeled goat
anti-mouse IgG antibody is purchased from Abcam, TMB
single-component substrate solution is purchased from Solarbio,
24-well plates and ELISA plates are purchased from Corning, Marburg
GP overlapping peptide library and CTL epitope LI-9 are synthesized
by Shanghai Gill Biochemical Company, DMSO, PMA and ionomycin are
purchased from Sigma, fetal bovine serum (PBS) and RPMI1640 mediums
are purchased from Gibco, truncated Marburg virus GP is expressed
and purified by our laboratory, 2N sulfuric acid, 70% alcohol and
PBS are self-prepared.
[0111] 2 Immunization of Mice
[0112] Based on the experimental design, the Marburg candidate
vaccines and the control vaccines are diluted with physiological
saline to specific concentrations, and mice are immunized by 1 mL
syringes via injection to medial muscle of the left posterior
thigh, with 50 .mu.L per mouse. The immune dose for each mouse is
1.times.10.sup.8 ifu, 1.times.10.sup.7 ifu, 1.times.10.sup.6 ifu or
1.times.10.sup.5 ifu, and groups of mice are shown in Table 1,
Table 2 and Table 3.
TABLE-US-00004 TABLE 1 Groups of mice for evaluating humoral immune
response Route of Number of mice Name of vaccine Dose immunization
in the group Ad5-MAGPopt 10.sup.8 ifu Intramuscularly 12
Ad5-MAGPopt 10.sup.7 ifu Intramuscularly 12 Ad5-MAGPopt 10.sup.6
ifu Intramuscularly 12 Ad5-MAGP 10.sup.8 ifu Intramuscularly 12
TABLE-US-00005 TABLE 2 Groups of mice for evaluating cellular
immune response Route of Number of mice Name of vaccine Dose
immunization in the group Ad5-MAGPopt 10.sup.8 ifu Intramuscularly
12 Ad5-MAGP 10.sup.8 ifu Intramuscularly 12 Ad5-Luc 10.sup.8 ifu
Intramuscularly 12
TABLE-US-00006 TABLE 3 Groups of mice for evaluatinge cellular
immune response at different doses Route of Number of mice Name of
vaccine Dose immunization in the group Ad5-MAGPopt 10.sup.8 ifu
Intramuscularly 6 Ad5-MAGPopt 10.sup.7 ifu Intramuscularly 6
Ad5-MAGPopt 10.sup.6 ifu Intramuscularly 6 Ad5-MAGPopt 10.sup.5 ifu
Intramuscularly 6 Ad5-Luc 10.sup.8 ifu Intramuscularly 6
[0113] 3. Humoral Immune Response
[0114] 3.1. Blood Collection and Serum Separation
[0115] Blood is collected from the immunized mice tail vein at
specific time points and left at room temperature for over 1 h.
Then it is centrifuged at 5000 rpm for 10 min, transferred to a new
tube and stored frozen at -20.degree. C. until further use.
[0116] 3.2 ELISA Test for Serum Antibody
[0117] On the day before experiment, ELISA plates are coated with
truncated Marburg virus GP protein (240 aa to 526 aa, prepared by
E. coli expression) at a concentration of 2 .mu.g/mL, 100
.mu.L/well, and left at 4.degree. C. overnight. On the day of
experiment, ELISA plates are washed 3 times with washing solution
(PBS+0.2% tween 20) in a plate washer. 120 .mu.L of blocking
solution (washing solution+2% BSA) is added to each well, and the
mixture is blocked for 1 hour at room temperature. After the plates
are washed 3 times in the plate washer, 100 .mu.L of sample
dilution buffer (washing solution+0.2% BSA) is added to each well.
Serum samples are diluted by a series of 3 times starting at an
indicated dilution and incubated at room temperature for 1 hour. 8
serial dilutions are set for each sample and 4 blank control wells
without serum are set for each plate. After the plates are washed 5
times, 100 .mu.L of HRP-labeled goat anti-mouse IgG antibody
(1:20,000 dilution) is added to each well, and the mixture is
incubated for 1 hour at room temperature. After washing 5 times,
100 .mu.L of TMB substrate solution is added to each well, and the
reaction is terminated with 2 mol/L sulfuric acid after 6 minutes
of color development. Finally, the absorbance at 450 nm is measured
using a microplate reader. Taking 2.1 times OD.sub.450 value of the
blank well as the cut-off value, the software GraphPad Prism is
used to calculate the antibody titer of each sample. The antibody
titer is defined as the reciprocal of the sample dilution
corresponding to 2.1 times OD.sub.450 value of the blank well.
[0118] Antibody data are shown in FIG. 8 and FIG. 9. Codon
optimization of MARV GP leads to significant increase in the serum
antibody levels induced by Ad5-MAGPopt. High levels of specific
antibodies are seen in BALB/c mice immunized with Ad5-MAGPopt
within 2 weeks, which last for over 63 weeks in mice. IgG antibody
levels of Ad5-MAGPopt in BALB/c mice show a certain dose-dependent
relationship.
[0119] 4. Cellular Immunity.
[0120] 4.1 Isolation of Splenic Lymphocytes
[0121] The mice are sacrificed by cervical dislocation and immersed
in 70% alcohol for about 3 min. The spleens are aseptically removed
from the mice and placed on the 200-mesh cell sieve in a sterile
plate. 10 mL of RPMI1640 complete medium is added, and spleens are
gently grinded into single cells with a syringe plunger. 10 mL of
RPMI1640 complete medium is added to rinse the cell sieve to obtain
more splenocyte. The splenocyte suspension is transferred to a 50
mL centrifuge tube and centrifuged at 500 g for 5 min. The
supernatant is discarded, and cells are resuspended in 3 mL of
1.times.erythrocyte lysis buffer and lysed for 5 minutes at room
temperature. 27 mL of RPMI1640 complete medium is added to each
tube, and the mixture is centrifuged at 500 g for 5 min. The
supernatant is discarded, and cells are washed again with 20 mL of
RPMI1640 complete medium. The cells are resuspended with an
appropriate volume of medium, filtered through a 200-mesh cell
sieve into a 10 mL test tube, counted, and placed on ice until
use.
[0122] 4.2 Flow Cytometry Detection of Specific T Cell Surface
Markers and Intracellular Cytokines
[0123] 4.2.1 In Vitro Stimulation of Mouse Splenocytes
[0124] The mouse spleen cells is taken for dilution to
4.times.10.sup.6 cells/mL, and added to a 24-well plate with 0.5 mL
per well. An specific CTL epitope stimulation well and a
non-stimulation well are set for each mouse. The specific CTL
epitope stimulators are MARV-GP overlapping peptide pool and a
MARV-GP CTL epitope LI-9 with a concentration of 2 .mu.g/mL per
peptide, the stimulation control is DMSO of the same amount as the
peptides. As positive controls, PMA and ionomycin stimulation wells
are added, wherein the PMA concentration is 100 ng/mL and the
ionomycin concentration is 1 .mu.g/mL. Meanwhile, 1 .mu.L of
Brilliant Violet 421.TM. anti-mouse CD107a is added to each well.
The cells are cultured at 37.degree. C. in 5% CO.sub.2 incubator
for 1 hour, then GolgiStop and/or GolgiPlug is added to each well
as the blocker of cytokine secretion. After a total of 6 hours of
culture, antigens are stained for flow cytometry detection of
intracellular cytokines.
[0125] 4.2.2 Cell Surface Antigen and Intracellular Cytokine
Staining
[0126] After in vitro stimulation for 6 hours, spleen cells are
transferred to flow tubes and centrifuged at 600 g for 5 minutes at
room temperature. The supernatant is discarded. Staining buffer 1
is prepared based on Table 4, with 50 .mu.L per tube, mixed gently,
and left at room temperature for 15 minutes in the dark. 3 mL of
PBS+2% FBS is added to each tube, and the mixture is centrifuged at
600 g for 5 minutes at room temperature. The supernatant is
discarded. Staining buffer 2 is prepared based on Table 4, with 50
.mu.L per tube, mixed gently, and left at room temperature for 20
minutes in the dark. 3 mL of PBS+2% FBS is added to each tube, and
the mixture is centrifuged at 600 g for 5 minutes at room
temperature. The supernatant is discarded. 200 .mu.L of
Cytofix/Cytoperm.TM. Fixation and Permeabilization Solution is
added to each tube, and the mixture is left at room temperature for
20 minutes in the dark to fix and perforate the cells. 1 mL of
1.times. Perm/Wash' buffer is added to each tube, and the mixture
is centrifuged at 800 g for 5 minutes at room temperature. The
supernatant is discarded. Staining buffer 3 is prepared based on
Table 4, with 50 .mu.L per tube, mixed gently, and left at room
temperature for 30 minutes in the dark. 2 mL of 1.times.
Perm/Wash.TM. buffer is added to each tube, and the mixture is
centrifuged at 800 g for 5 minutes at room temperature. The
supernatant is discarded. 3 mL of PBS is added to each tube, and
the mixture is centrifuged at 800 g for 5 minutes at room
temperature. The supernatant is discarded. Cells in each tube are
resuspend with 150 .mu.L PBS, and left at 4.degree. C. in the dark,
until further test.
TABLE-US-00007 TABLE 4 Table of flow cytometry staining buffer
preparation (unit, .mu.L) Volume (per Component preparation) PBS
(staining buffer 1) 50.0 LIVE/DEAD .TM. Fixable Near-IR 0.25
.mu.L/mL Dead Cell Stain Buffer Mouse BD Fc Block .TM. 1.0 PBS + 2%
FBS (staining buffer 2) 50.0 APC/Cy7 anti-mouse CD14 0.25 APC/Cy7
anti-mouse CD19 0.15 Alexa Fluor .RTM. 700 anti-mouse CD4 0.15 1
.times. Perm/Wash .TM. Buffer (staining 50.0 buffer 3) PerCP/Cy5.5
anti-mouse CD3 0.20 FITC anti-mouse CD8a 0.10 PE anti-mouse
IFN.gamma. 0.25 PE/Cy7 anti-mouse TNF 0.50 Brilliant Violet 605
.TM. anti-mouse 0.50 IL-2 Brilliant Violet 510 .TM. anti-mouse 0.50
CD154
[0127] 4.2.3 Test on the Machine
[0128] BD FACS Canto.TM. is used for flow cytometry. Firstly, the
voltage of each channel is regulated to the appropriate level, and
single-fluorescent stained samples are used to adjust the
fluorescence compensation between dyes. Then, samples are loaded in
order and data are collected. Single cells are gated by FSC-A and
FSC-H, lymphocytes are gated by FSC and SSC, living CD3 cells are
gated by PerCP/Cy5.5 and APC/Cy7, and CD8.sup.+ T cells and
CD4.sup.+ T cells are gated by FITC and Alexa Fluor.RTM. 700.
Finally, the PE channel, PE/Cy7 channel, Brilliant Violet 605
channel, Brilliant Violet 421 and Brilliant Violet 510 channels are
used to count the percentage of IFN.gamma., TNF, IL-2, CD107a and
CD154 positive cells in CD8.sup.+ T cells and CD4.sup.+ T cells,
respectively.
[0129] 4.2.4 Intracellular Cytokine Staining
[0130] The intracellular cytokine staining show that after
splenocytes from Ad5-MAGPopt-immunized mice are stimulated by
MARV-GP overlapping peptide pool and MARV-GP CTL epitope LI-9,
CD8.sup.+ T cells and CD4.sup.+ T cells can secrete a large amount
of IFN-.gamma., TNF-.alpha., and IL-2 cytokines, with remarkably
higher expression of cytotoxicity marker CD107a, which is
significantly higher than that of the immunization with
non-codon-optimized Ad5-MAGP group and the control Ad5-Luc group
(see FIG. 10, NS, P>0.05; ***, P<0.001). Meanwhile,
remarkably higher expression of CD154 on CD4.sup.+ T cells is
detected in spleen cells from Ad5-MAGPopt-immunized mice (see FIG.
13), suggesting that specific T cells induced by Ad5-MAGPopt can
activate B cells. Cellular immune response of mice immunized with
Ad5-MAGPopt at different dose indicate that the difference of
cellular immune response (IFN-.gamma., TNF-.alpha., IL-2, and
CD107a) of CD8.sup.+ T cells and CD4.sup.+ T cells induced by
Ad5-MAGPopt at 1.times.10.sup.8 ifu, 1.times.10.sup.7 ifu,
1.times.10.sup.6 ifu or 1.times.10.sup.5 ifu between BALB/c mice
immunized with the above dose is not significantly different via
analysis of variance (see FIG. 11 and FIG. 12).
[0131] 4.3. ELISPOT Assay of Cytokines
[0132] BD.TM. ELISPOT mouse IFN-.gamma. Set is used for ELISPOT
assay of IFN-.gamma.. The procedure is conducted according to the
kit instructions. ELISPOT plate is coated with 5 .mu.g/mL
anti-mouse IFN-.gamma. antibody and left at 4.degree. C. overnight.
RPMI 1640+10% FBS medium is used to block the plate at room
temperature for 2 hour. Discard the blocking solution, 50 .mu.L of
RPMI1640+10% FBS medium containing MARV-GP overlapping peptide pool
and MARV-GP CTL epitope LI-9 (concentration, 2 .mu.g/mL per
peptide) or non-stimulation control medium containing the same
volume of DMSO is added to each well in advance according to the
layout of the plate. 50 .mu.L of isolated spleen cells
(4.times.10.sup.6 cells/mL) are added to the specific wells, with
two wells of peptide stimulation and two wells without stimulation
for each mouse. Cells are cultured at 37.degree. C. in 5% CO.sub.2
incubator for 12-24 hours. The following day, cells in the plate
are discarded, the plates are washed twice with 200 .mu.L distilled
water, and then washed 3 times with washing solution (PBS+0.05%
tween-20), left for 2-3 minutes each time. Discard the washing
solution, added 100 .mu.L biotinylated anti-mouse IFN.gamma.
(diluted at 1:250 in PBS+10% FBS) in each well, and incubate at
room temperature for 2 hours. The plates are washed 3 times with
washing solution, left for 2-3 minutes each time. Add 100 .mu.L
streptavidin-horseradish peroxidase (diluted at 1:100 in PBS+10%
FBS) in each well, and incubate at room temperature for 1 hour.
Wash the plates for 4 times with washing solution, and 3 times with
PBS. Develop the spots with BD.TM. ELISPOT AEC substrate set. When
the spots in the wells grow to a suitable size (usually reaction at
room temperature for 15-25 minutes), discard the substrate
solution, and terminate the reaction by washing extensively in
deionized water. After the plate is dried, count the spots with an
enzyme-linked spot imaging analysis system.
[0133] Similar to the intracellular cytokine test by flow
cytometry, after splenocytes from Ad5-MAGPopt immunized mice are
stimulated by Marburg GP overlapping peptide pool and Marburg GP
CTL epitope LI-9, a large amount of specific IFN-.gamma. spots
appear, which is significantly higher than that of Ad5-MAGP group
and the Ad5-Luc control group (see FIG. 14, NS, P>0.05; **,
P<0.01, ***, P<0.001). Meanwhile, specific IFN.gamma. spots
induced by different doses (1.times.10.sup.8 ifu, 1.times.10.sup.7
ifu, 1.times.10.sup.6 ifu and 1.times.10.sup.5 ifu) of Ad5-MAGPopt
in immunized BALB/c mice show no dose-dependence effect via
analysis of variance (see FIG. 15).
[0134] 5. Summary of Immunological Evaluation
[0135] Intramuscular injection of MARV-GP codon-optimized Marburg
virus disease vaccine Ad5-MAGPopt induces strong humoral and
cellular immune responses in the immunized BALB/c mice.
Example 3. Evaluation on the Protective Efficacy of Ad5-MAGPopt on
Mouse Models
[0136] SPF BALB/c mice (4-6 weeks old) are divided into 4 groups
(see Table 5), and intramuscularly injected with Ad5-MAGPopt
(rename as Ad5-MARV) at 10.sup.8 ifu, 10.sup.7 ifu or 10.sup.6 ifu,
or PBS of equal volume. Four weeks after immunization, mice are
transferred to the biosafety level 4 laboratory for MA-MARV
(Marburg virus mouse adaptive strains) challenge by intraperitoneal
injection and the challenge dose is 2000.times. LD.sub.50. The
survival and weight changes of the mice are recorded within 14 days
after challenge, and the survival are recorded for an additional 14
days.
TABLE-US-00008 TABLE 5 Groups of study on the protective efficacy
of Ad5-MAGPopt Route of Number of mice Name Dose immunization in
the group Ad5-MARV 10.sup.8 ifu Intramuscularly 10 Ad5-MARV
10.sup.7 ifu Intramuscularly 10 Ad5-MARV 10.sup.6 ifu
Intramuscularly 10 PBS 0 ifu Intramuscularly 10
[0137] 28 days after immunization, MA-MARV challenge is conducted
in mice immunized with Ad5-MARV at different dose levels or control
mice. All mice immunized with the Ad5-MARV (10.sup.8 ifu/mouse,
10.sup.7 ifu/mouse, and 10.sup.6 ifu/mouse) survive, but all mice
in PBS control group die within 6 to 8 days after challenge (see
FIG. 16). None of Ad5-MARV-immunized mice experience weight loss
within 14 days after challenge, but those in the PBS control group
begin to lose weight on day 3 after challenge until death (see FIG.
17).
INDUSTRIAL APPLICABILITY
[0138] The present invention discloses a Marburg virus disease
vaccine with human replication-deficient adenovirus as vector, a
preparation method and a use in the preparation of vaccine agents.
The Marburg virus disease vaccine provided by the present invention
is easy for industrial production, with industrial applicability.
Sequence CWU 1
1
212088DNAMarburg virus 1ccaagcttgc cgccaccatg gacgccatga agcggggcct
ctgctgtgtt ctgctgctct 60gcggcgccgt gttcgtgagt aactcgttac ccattctgga
gattgccagc aacatccagc 120cccagaacgt ggattccgtg tgctccggca
ccctgcagaa gaccgaagat gtccatctca 180tgggcttcac cctgtccggg
cagaaggtcg ccgactcgcc cctggaggcc agcaagcgct 240gggccttccg
cgcaggcgtc cctcctaaga acgtggaata cacggaggga gaggaggcca
300agacttgtta caacatctca gtaaccgacc cctccggtaa aagtctcctg
ctcgaccctc 360cgacgaacat ccgcgactac cccaagtgca agacaatcca
ccacattcag ggccagaatc 420cgcacgccca gggtatcgcc ctgcacctgt
ggggcgcttt tttcctgtac gaccgaatcg 480cctccaccac catgtaccgg
gggaaggttt ttaccgaggg caatatcgcc gccatgattg 540tgaataagac
cgtccacaag atgatcttct ccaggcaggg gcagggatac cggcacatga
600acctgacctc cactaacaag tactggacta gttccaacgg tacccagacc
aacgacactg 660gctgctttgg gaccctccag gagtacaact ccaccaaaaa
ccagacttgt gccccgtcca 720aaaagcccct gcccctgcct accgcccacc
cggaagtgaa gctgacatct acatcgaccg 780acgcaacaaa actcaatact
accgacccca atagtgacga cgaggacctg accaccagtg 840gcagcggctc
cggcgagcag gagccataca ccacctcgga cgcagcaacc aagcagggcc
900tgtcgtccac gatgccgcct accccgtcgc cccagccctc gaccccgcag
cagggcggca 960ataataccaa ccattctcag ggggtcgtta ccgagcccgg
caagaccaac acgactgctc 1020agccatccat gccaccccac aacaccacca
ctatctcgac caacaacact tcaaagcaca 1080acctctcgac ccccagtgtc
ccaatccaga acgccaccaa ctataacacg cagtccacag 1140cgcccgagaa
cgagcagaca agtgccccct ctaagacgac cctcctcccc accgagaacc
1200ccacaaccgc caagtccacc aactcaacca agtcccccac gacgaccgtt
cccaacacca 1260ccaacaagta ctcaacctct ccttcgccta ccccaaactc
caccgcgcag caccttgtgt 1320acttccgccg gaagcgaaac atcctgtggc
gcgagggaga catgttccct ttcctcgatg 1380gactgatcaa cgcccccatc
gactttgatc cagtccccaa caccaagacg atcttcgatg 1440aaagtagtag
ttcgggggct agtgcagaag aggaccagca tgcgagtcct aacatctccc
1500tgaccctctc ctacttcccc aaggtgaacg agaataccgc ccactccggc
gagaatgaga 1560acgattgcga tgccgaactg aggatctgga gtgtgcagga
ggacgacctg gcggctggcc 1620tgtcttggat ccccttcttt gggccgggca
tcgagggcct gtacaccgcc ggcctgatta 1680aaaaccagaa caacctggtt
tgccgcctga gaagactggc aaaccagact gccaagtccc 1740tggaactgct
cttacgcgtc accaccgagg agcggacctt ttcgctcatc aaccgccacg
1800ccatcgactt cctgctggcc cggtggggcg gtacgtgcaa agtgctgggc
cccgactgct 1860gcatcggcat cgaggatctc agccgcaaca tctctgagca
aatcgatcag atcaagaagg 1920atgagcagaa ggaaggtacc ggctggggcc
tgggggggaa gtggtggacc agtgactggg 1980gcgtgctgac taacctgggc
atcctgctgc tgctatcgat cgccgtgctc atcgccctgt 2040cttgcatctg
ccgtatcttc accaaatata tcggctaagt cgacgtct 208822073DNAMarburg virus
2ccaagcttgc cgccaccatg aaaaccacat gtctccttat cagtcttatc ttaatccaag
60gggtaaaaac tctccctatt ttagagatag ccagtaacat tcaaccccaa aatgtggatt
120cagtatgctc cgggactctc cagaagacag aagacgttca tctgatggga
ttcacactga 180gcgggcaaaa agttgctgat tcccctttag aggcatccaa
acgatgggcc ttcagggcag 240gtgtacctcc caagaatgtt gagtatacag
aaggggagga agctaaaaca tgttacaata 300taagtgtaac ggatccctct
ggaaaatcct tgctgttaga tcctcctacc aacatccgtg 360actatcctaa
atgcaaaact atccatcata ttcaaggtca aaaccctcat gcacagggga
420tcgctctcca tttgtgggga gcatttttct tgtatgatcg catcgcctcc
acaacgatgt 480atcgaggcaa agtcttcact gaagggaaca tagcagctat
gattgtcaat aagacagtgc 540acaaaatgat tttctcgagg caaggacaag
ggtaccgtca catgaaccta acttctacta 600ataaatattg gacaagtagc
aacggaacgc aaacgaatga cactggatgc ttcggtactc 660ttcaagaata
taattctaca aagaaccaaa catgtgctcc gtccaaaaaa cctttaccac
720tgcccacagc ccatccggag gtcaagctca ctagcacctc aactgatgcc
accaaactca 780ataccacaga cccaaacagt gatgatgagg acctcacaac
atctggctca gggtctggag 840aacaggaacc ttacacaact tctgacgcag
ccacgaagca agggctttca tcaacaatgc 900cgcccactcc ctcaccacaa
ccaagcacgc cacagcaagg aggaaacaac acgaaccatt 960cccaaggtgt
tgtgactgaa cccggcaaaa ccaacacaac tgcacaaccg tccatgcccc
1020ctcacaacac tactacaatc tctactaaca acacctccaa gcacaacctc
agcactccct 1080ctgtaccaat acaaaatgcc actaattaca acacacagag
cacggcccct gaaaatgagc 1140aaaccagtgc cccctcgaaa acaaccctgc
ttccaacaga aaatcctaca acagcaaaga 1200gcaccaatag tacaaaaagc
cccactacaa cagtaccaaa tacgacaaat aagtattcca 1260ccagtccctc
ccccaccccc aactcgactg cacaacatct tgtatatttc agaaggaaac
1320gaaatattct ctggagggaa ggcgacatgt tcccttttct ggatgggtta
ataaatgctc 1380cgattgattt tgatccggtt ccaaatacaa agacaatctt
tgatgaatcc tctagttctg 1440gtgcttcagc tgaggaagat cagcatgcct
cccctaatat cagtttaact ttatcttact 1500ttcctaaggt aaatgaaaac
actgcccact ctggagaaaa tgaaaatgat tgtgatgcag 1560agttaagaat
ttggagtgtt caggaggacg acctggcagc aggactcagt tggataccgt
1620tttttggccc tggaatcgaa ggactttata ctgctggttt aattaaaaat
caaaataatt 1680tggtttgcag gttgaggcgt ctagccaatc agactgccaa
atccttggaa ctcttattaa 1740gagtcacaac cgaggaaaga acattttcct
taatcaatag acatgccatt gattttttac 1800tcgcaaggtg gggaggaaca
tgcaaagtgc ttggacctga ttgttgcatc ggaatagaag 1860acttgtccag
aaatatttca gaacaaattg atcaaatcaa aaaggacgaa caaaaagagg
1920ggactggttg gggtctgggt ggtaaatggt ggacatcaga ctggggtgtt
cttactaact 1980tgggcatctt gctactactg tccatagctg tcttaattgc
tctgtcctgt atttgtcgta 2040tttttactaa atatattgga taagtcgacg tct
2073
* * * * *